Skip to content
Home/Companies/Biotech/Modus Therapeutics
Modus Therapeutics

Modus Therapeutics

Biotech·Sweden·Exited 2021·Held 8yr
Entry
2013
Hold
8yr
Exit
2021

Who owns Modus Therapeutics?

Modus Therapeutics was owned by Rosetta Capital through Rosetta Capital IV (2013 vintage) from 2013 to 2021, exited via IPO.

Hand-verified · updated 2026-07-16

Rosetta Capital
Investor
Rosetta Capital
Rosetta Capital IV · 2013 · Secondaries

Key facts

HQSweden
SectorBiotech
StatusAcquired
Websitemodustx.com
Exit Type
IPO
Buyer
–
MOIC
–
Exit Year
2021

More from Rosetta Capital IV

Other portfolio companies in the same fund.

Akinion Pharmaceuticals
Active
PharmaSweden· 2013
Aprea Therapeutics
Exited 2019
BiotechSweden· 2013
Axelar
Active
BiotechSweden· 2013
Biosergen
Exited 2021
BiotechSweden· 2013
Clanotech
Active
BiotechSweden· 2013
Dilafor
Dilafor
Active
BiotechSweden· 2013

More PE-backed in Biotech

Comparable biotech deals from other GPs.

Antiverse
Antiverse
Active
Future Planet CapitalUK
CellCentric
CellCentric
Active
Future Planet CapitalUK
Crescendo Biologics
Crescendo Biologics
Active
Future Planet CapitalUK
Cytox Group
Exited 2024
Future Planet CapitalUK
GenSight Biologics
GenSight Biologics
Active
Sofinnova PartnersFrance
Healx
Healx
Active
Amadeus Capital PartnersUK
Track Modus Therapeutics

Save this record to your watchlist and pick up your research where you left off. No spam.

Create free account

Get the full record on Modus Therapeutics.

Free. No credit card. 30 seconds. Exit buyers and MOIC on Pro.

Hand-checked deal notes on this investment
Save this company to your watchlist
Exit buyer and MOIC on this deal (Pro)
or
Continue with email

Already a member? Sign in

Look up another firm or company
Data refreshed weekly · Sourced from public filings · Report an issue